Fabentech develops emergency polyclonal antibody treatments against biological threat agents and emerging infectious diseases, working with French defence and health authorities. It has raised around $15 million.
Polyclonal antibody countermeasures against bioterrorism agents and outbreaks
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
-
Total raised
-
Valuation
72
Employees
2009
Founded
Latest round
Debt - October 1, 2024
Debt - €20,000,000
Debt
October 1, 2024
European Investment Bank
Open roles
Fabentech is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile